Persistent Negative Symptoms in Schizophrenia: An Overview

	Tweet

Persistent negative symptoms represent an alternative approach for assessing negative symptoms in the context of clinical trials.

Persistent negative symptoms are designed to capture those symptoms that lead to functional impairment but are currently understudied and for which there are no currently available effective treatments. 

Persistent negative symptoms differ from the 2 most commonly used approaches: primary, enduring negative symptoms or deficit symptoms and negative symptoms broadly defined to include negative symptoms, regardless of their etiology or duration.

In contrast to deficit symptoms, persistent negative symptoms may include secondary negative symptoms. However, in contrast to negative symptoms broadly defined, the secondary negative symptoms included in the assessment of persistent negative symptoms only include those that have failed to respond to usual treatments for secondary negative symptoms.

In consequence, the presence of persistent negative symptoms identifies a patient population with clinically relevant symptomatology, which is larger than the one with the deficit syndrome but less heterogeneous than that captured through the use of a nonrestrictive definition of negative symptoms. This may facilitate the selection of subjects for inclusion into research and efforts to develop new pharmacological treatments and enhance our understanding of a relevant clinical problem.

Ultimately, the investigation of the different entities characterized by negative symptoms, such as persistent negative symptoms, and the enhanced understanding of their biological and clinical characteristics may help to unravel the psychopathological and biological heterogeneity of schizophrenia.

Keywords: persistent negative symptoms / deficit syndrome / negative symptoms / schizophrenia / pharmacological treatment

Robert W. Buchanan
Department of Psychiatry, University of Maryland, School of Medicine, Maryland Psychiatry Research Center, PO Box 21247, Baltimore, MD 21228

To whom correspondence should be addressed; tel: 410-402-7876, fax: 410-402-7198, e-mail: .

Schizophrenia Bulletin Advance Access originally published online on November 10, 2006
Schizophrenia Bulletin 2007 33(4):1013-1022; doi:10.1093/schbul/sbl057

Full text

RELATED STORIES:
Schizophrenia Course and Outcome   Glutamate: Too much of a good thing in schizophrenia?   “Schizophrenia” should be dropped, say experts   Antipsychotic treatment response and serum levels in men and women   Schizophrenia Treatment and Outcome   Clozaril useful as second schizophrenia drug   How do we determine if a treatment is working?   Obesity and Mental Illness   Schizophrenia-type illness linked to heart risk   Schizophrenia Social Skills Training   Brain Differences in schizophrenia   Depression and schizophrenia top mental health admissions   Models of schizophrenia   Schizophrenia - Interviewing Guidelines   Brain development goes off track as vulnerable individuals develop schizophrenia

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]